Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Snjezana Dotlic
Based on 3 articles published since 2008
||||

Between 2008 and 2019, Snjezana Dotlić wrote the following 3 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [CROATIAN SOCIETY FOR MEDICAL ONCOLOGY CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP OF PATIENTS WITH MELANOMA]. 2016

Herceg, Davorin / Buzina, Daska Stulhofer / Ceović, Romana / Dotlić, Snjezana / Ilić, Ivana / Orehovec, Sanda Smuđ / Herceg, Gordana Horvatić / Mijatović, Davor / Separović, Robert / Silovski, Tajana / Vrbanec, Damir. · ·Lijec Vjesn · Pubmed #27290810.

ABSTRACT: Melanoma in the Western world has an increasing incidence. One of the most important factor for the increase in incidence is sporadic, uncontrolled exposure to the sun. The basis for the treatment of primary melanoma is surgical treatment. Treatment of metastatic disease of melanoma in recent years experienced significant changes. BRAF and MEK inhibitors, immunotherapy with programmed cell-death immune checkpoint inhibitors (anti-PD-1-antibodies) are new options for the treatment of metastatic disease. A mulitidisiplinary team of Croatian Society for Medical Oncology provides recommendations for diagnosis, treatment and follow-up of melanoma primarily driven to the discovery of new drugs and therapeutic options, that change the prognosis of patients with metastatic melanoma.

2 Article Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. 2016

Lukenda, Adrian / Dotlic, Snjezana / Vukojevic, Nenad / Saric, Borna / Vranic, Semir / Zarkovic, Kamelija. ·Ocna poliklinika Opto Centar, Zagreb, Croatia. · Department of Pathology and Cytology, University Hospital Center Zagreb, Zagreb, Croatia. · Department of Ophthalmology, University Hospital Center Zagreb, Zagreb, Croatia. · Ophthalmology Clinic, University Hospital "Sveti Duh", Zagreb, Croatia. · Department of Pathology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina. · Department of Pathology, Zagreb University School of Medicine, Zagreb, Croatia. ·J Clin Pathol · Pubmed #26290260.

ABSTRACT: AIMS: The aim of the present study was to immunohistochemically investigate the expression and prognostic significance of putative cancer stem cell markers CD117 (c-kit), CD34, CD20 and CD15 in a cohort of patients with primary choroidal and ciliary body melanoma. METHODS: The immunohistochemical expression of these markers was evaluated using 3,3'-diaminobenzidine tetrahydrochloride (DAB) and 3-amino-9-ethylcarbazole (AEC) chromogens on paraffin-embedded tissue samples from 40 patients who underwent enucleation in the period from 1985 through 2000. Thirty-one patients had adequate tissue specimens for the analysis. RESULTS: CD117 overexpression was observed in 12 of the 31 samples (39%) when AEC chromogen was used and in 14 of 26 (54%) samples when DAB was used. CD15 positivity was seen in three out of 30 (10%) samples with AEC and in six out of 26 (23%) samples with DAB. CD20 and CD34 exhibited no positivity in the tested samples. During the average follow-up time of 8.7 years (range 0.5-22 years), 17 patients (55%) died due to metastatic disease. The Kaplan-Meier plots showed a significantly shorter overall and disease-free survival in CD117-positive patients when the AEC chromogen was used. CD15 expression was not associated with patients' survival. In multivariate analysis, patients expressing the CD117 AEC had 4.13 times higher risk of lethal outcome in comparison with CD117 AEC negative patients. CONCLUSIONS: Our retrospective cohort study has for the first time demonstrated a small proportion of CD15-positive uveal melanomas. CD117 AEC overexpression was associated with a worse outcome in patients with choroidal and ciliary body melanoma. Further studies should confirm the validity of these observations and their potential for targeted treatment modalities.

3 Article Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine--a metastatic disease 17 years after complete surgical resection. 2011

Katalinic, Darko / Anic, Branimir / Stern-Padovan, Ranka / Mayer, Miroslav / Sentic, Mirna / Cikes, Nada / Zarkovic, Kamelija / Dotlic, Snjezana / Plestina, Stjepko. ·Department of Oncology, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia. darko.katalinic@kbc-zagreb.hr ·World J Surg Oncol · Pubmed #22093436.

ABSTRACT: Primary spinal melanomas are extremely rare lesions. In 1906, Hirschberg reported the first primary spinal melanoma, and since then only 40 new cases have been reported. A 47-year-old man was admitted suffering from low back pain, fatigue and loss of body weight persisting for three months. He had a 17-year-old history of an operated primary spinal melanoma from T7-T9, which had remained stable for these 17 years. Routine laboratory findings and clinical symptoms aroused suspicion of a metastatic disease. Multislice computed tomography and magnetic resonance imaging revealed stage-IV melanoma with thoracic, abdominal and skeletal metastases without the recurrence of the primary process. Transiliac crest core bone biopsy confirmed the diagnosis of metastatic melanoma. It is important to know that in all cases of back ore skeletal pain and unexplained weight loss, malignancy must always be considered in the differential diagnosis, especially in the subjects with a positive medical history. Patients who have back, skeletal, or joint pain that is unresponsive to a few weeks of conservative treatment or have known risk factors with or without serious etiology, are candidates for imaging studies. The present case demonstrates that complete surgical resection alone may result in a favourable outcome, but regular medical follow-up for an extended period, with the purpose of an early detection of a metastatic disease, is highly recommended.